Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTConnect Biopharma Holdings Ltd's latest supported as-filed period reports revenue of $2.8M, 5666.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -575.22% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 5666.67% · CORE
Level · gp.fundamentals.operating_margin
Raw value -635.98% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 587.90% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 45.56% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -33.5% from the comparable as-filed period.
Net income changed -34.0% from the comparable as-filed period.
Operating income changed -31.1% from the comparable as-filed period.
Operating margin changed +2733068 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
CNTB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001835268-26-000028SEC ↗8-KAug 12, 2026Period Aug 12, 20260001835268-26-000027SEC ↗4Jul 1, 2026Period Jun 30, 20260001835268-26-000022SEC ↗4Jul 1, 2026Period Jun 30, 20260001835268-26-000021SEC ↗4Jun 2, 2026Period May 29, 20260001193125-26-253607SEC ↗10-QMay 12, 2026Period Mar 31, 20260001835268-26-000020SEC ↗8-KMay 12, 2026Period May 12, 20260001835268-26-000019SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 1, 2026 | Xanthopoulos Kleanthis GabrielDirector | Grant Or AwardDirect | 3,738 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +85.5% from the comparable as-filed period.
Revenue changed +5666.7% from the comparable as-filed period.
Stock-based compensation changed +32.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001835268-26-000016